Get started
Work

21P Progression-free survival and overall survival with pumitamig (PD-L1 × VEGF-A bsAb) plus chemotherapy in patients with EGFR-mutated advanced non-small cell lung cancer following progression with EGFR TKI in China: Phase II study results

Year: 2026
Type: article
Study design: Clinical Trial
Abstract: Pumitamig (BNT327/BMS986545) is an investigational bispecific antibody designed to target both PD-L1 and VEGF-A in the tumor and tumor microenvironment that has shown encouraging antitumor activity in combination with chemo in pts with previously treated EGFR-mutated NSCLC. Here, we present PFS and OS data from an ongoing single-arm phase II study of pumitamig + chemo in pts with EGFR-mutated advanced NSCLC who progressed on or after standard EGFR TKI treatment.
Source: ESMO Open
DOI: 10.1016/j.esmoop.2026.106328
Authors: Y-L. Wu, Z. Wang, H. Liu, J. Fang, X. Meng, Y. Pan, H. Zhao, Y. Zhao, H. Su, M. Sun, T. Zhou, P. Duan, D. Lv, Y. Wang, Y. Du, W. Zuo, C. Hu, S. He, P. Zhang, T. Zhang
Institutions: Guangdong Provincial People's Hospital, Jilin Province Tumor Hospital, Peking University Cancer Hospital, Shandong Tumor Hospital, Shandong First Medical University, University of Science and Technology of China, Anhui Provincial Hospital, Shanghai Sixth People's Hospital, Zhengzhou University, Henan Cancer Hospital, Tang Du Hospital, Air Force Medical University, Zhejiang Taizhou Hospital, Harbin Medical University, Third Affiliated Hospital of Harbin Medical University, First Affiliated Hospital of Anhui Medical University, First Affiliated Hospital of Nanchang University, Shanghai Pulmonary Hospital, The Affiliated Yongchuan Hospital of Chongqing Medical University
Language: English
Field: Medicine
Open Access status: gold
Estimated APC paid: $3,910
Funder: BioNTech
OpenAlex ID: W7137828594
FWCI:
Cites:
Cited by:
Related to: